Megron ER
Generic Name
Sumatriptan Succinate (Extended Release)
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| megron er 25 mg tablet | ৳ 30.00 | ৳ 420.00 |
| megron er 50 mg tablet | ৳ 50.00 | ৳ 500.00 |
Description
Overview of the medicine
Megron ER is an extended-release tablet containing Sumatriptan Succinate, primarily used for the acute treatment of migraine attacks with or without aura in adults.
Uses & Indications
Dosage
Adults
100 mg orally once daily for acute migraine. Max 200 mg in 24 hours.
Elderly
Use with caution. Lower doses may be considered, particularly with impaired renal or hepatic function.
Renal_impairment
No specific dose adjustment required, but use with caution due to excretion primarily via kidneys.
How to Take
Take orally with water, with or without food. Do not crush, chew, or split the extended-release tablet.
Mechanism of Action
Sumatriptan acts as a selective agonist for 5-hydroxytryptamine1 (5-HT1) receptors, particularly 5-HT1B and 5-HT1D subtypes, found on intracranial blood vessels and sensory nerves. It causes vasoconstriction of cranial arteries and inhibits the release of pro-inflammatory neuropeptides, thereby alleviating migraine symptoms.
Pharmacokinetics
Onset
Approximately 30 minutes to 1 hour for oral tablet, extended for ER formulation.
Excretion
Excreted mainly via urine, as inactive metabolites and unchanged drug.
Half life
About 2 hours for immediate-release, potentially longer for ER.
Absorption
Rapidly absorbed after oral administration, but with a variable bioavailability due to first-pass metabolism. ER formulation provides sustained release.
Metabolism
Primarily hepatic metabolism via monoamine oxidase A (MAO-A).
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, myocardial infarction)
- Cerebrovascular syndromes (e.g., stroke, TIA)
- Peripheral vascular disease
- Uncontrolled hypertension
- Severe hepatic impairment
- Concomitant use with MAOIs (within 2 weeks)
- Concomitant use with ergotamine-containing medications or other 5-HT1 agonists.
Drug Interactions
MAOIs
Increased plasma levels of sumatriptan, risk of serotonin syndrome.
SSRIs/SNRIs
Potential for serotonin syndrome.
Ergotamine-containing drugs or other triptans
Additive vasoconstrictor effects, risk of prolonged vasospasm.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms include convulsions, tremor, paralysis, redness, decreased activity, respiratory depression, ptosis, lacrimation, salivation. Treatment is supportive and symptomatic; monitor cardiovascular function.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Excreted into breast milk, advise caution or temporary discontinuation of breastfeeding.
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, myocardial infarction)
- Cerebrovascular syndromes (e.g., stroke, TIA)
- Peripheral vascular disease
- Uncontrolled hypertension
- Severe hepatic impairment
- Concomitant use with MAOIs (within 2 weeks)
- Concomitant use with ergotamine-containing medications or other 5-HT1 agonists.
Drug Interactions
MAOIs
Increased plasma levels of sumatriptan, risk of serotonin syndrome.
SSRIs/SNRIs
Potential for serotonin syndrome.
Ergotamine-containing drugs or other triptans
Additive vasoconstrictor effects, risk of prolonged vasospasm.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms include convulsions, tremor, paralysis, redness, decreased activity, respiratory depression, ptosis, lacrimation, salivation. Treatment is supportive and symptomatic; monitor cardiovascular function.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Excreted into breast milk, advise caution or temporary discontinuation of breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies nationwide
Approval Status
Approved by DGDA
Patent Status
Patent expired
Clinical Trials
Numerous clinical trials have established the efficacy and safety of sumatriptan for acute migraine treatment.
Lab Monitoring
- No specific routine lab monitoring required.
- Monitor cardiovascular function in patients with risk factors.
Doctor Notes
- Confirm migraine diagnosis before prescribing.
- Caution in patients with cardiovascular risk factors.
- Educate patients on proper use and warning signs.
Patient Guidelines
- Take at the first sign of a migraine headache.
- Do not take more than two doses in 24 hours.
- Do not use for prevention of migraine.
- Avoid driving or operating machinery if experiencing dizziness or drowsiness.
Missed Dose Advice
As this is an acute treatment, take only when a migraine attack occurs. Do not take regularly.
Driving Precautions
May cause drowsiness or dizziness. Patients should be advised to assess their ability to perform tasks requiring mental alertness, such as driving or operating machinery, before engaging in such activities.
Lifestyle Advice
- Identify and avoid migraine triggers (e.g., certain foods, stress, lack of sleep).
- Maintain a regular sleep schedule and reduce stress.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.